

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

*This English version is intended to be a reference material to provide convenience for users.*

*In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of PRECAUTIONS

## Eplerenone

March 17, 2026

### **Therapeutic category**

Antihypertensives

### **Non-proprietary name**

Eplerenone

### **Safety measure**

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.  
 This English version is intended to be a reference material to provide convenience for users.  
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current			Revision		
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving the following drugs: Itraconazole, voriconazole, posaconazole, preparations containing ritonavir, and ensitrelvir fumaric acid			2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving the following drugs: Itraconazole, voriconazole, posaconazole, preparations containing ritonavir, <u>preparations containing cobicistat, ceritinib,</u> and ensitrelvir fumaric acid		
10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following.) <Common to all indications>			10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following.) <Common to all indications>		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Itraconazole Voriconazole Posaconazole Preparations containing ritonavir Ensitrelvir fumaric acid	The plasma concentration of eplerenone may increase, and an increase in serum potassium levels may be induced.	The metabolism of eplerenone is suppressed by strong CYP3A4 inhibitor.	Itraconazole Voriconazole Posaconazole Preparations containing ritonavir <u>Preparations containing cobicistat</u> <u>Ceritinib</u> Ensitrelvir fumaric acid	The plasma concentration of eplerenone may increase, and an increase in serum potassium levels may be induced.	The metabolism of eplerenone is suppressed by strong CYP3A4 inhibitor.